These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24881922)

  • 1. [Acquired factor X deficiency developed four years after autologous transplantation in a patient with multiple myeloma associated with systemic AL amyloidosis].
    Takemura T; Fukatsu Y; Nagata Y; Asahina A; Yokota D; Hirano I; Yagyu T; Ono T; Katsumi A; Ohnishi K
    Rinsho Ketsueki; 2014 May; 55(5):558-62. PubMed ID: 24881922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
    Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
    Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
    Iwadate D; Hasegawa E; Hoshino J; Hayami N; Sumida K; Yamanouchi M; Sekine A; Kawada M; Hiramatsu R; Suwabe T; Sawa N; Yuasa M; Wake A; Fujii T; Ohashi K; Takaichi K; Ubara Y
    Intern Med; 2018 Mar; 57(5):701-706. PubMed ID: 29093408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired factor X deficiency in light chain amyloidosis: a report of 2 Korean cases.
    Ma Y; Kwon EH; Lee JE; Kim K; Kim HJ; Kim SH
    Korean J Lab Med; 2011 Jul; 31(3):154-6. PubMed ID: 21779187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
    Breems DA; Sonneveld P; de Man RA; Leebeek FW
    Eur J Haematol; 2004 Mar; 72(3):181-5. PubMed ID: 14962236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fatal hepatic failure due to AL amyloidosis in a patient with multiple myeloma].
    Tabata S; Kurata M; Takeda J; Funayama Y; Yamauchi N; Aoki K; Kato A; Ono Y; Arima H; Takiuchi Y; Nagano S; Matsushita A; Imai Y; Ishikawa T; Takahashi T
    Rinsho Ketsueki; 2012 Nov; 53(11):1906-10. PubMed ID: 23257671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Improvement of hepatomegaly after treatment with autologous hematopoietic stem cell transplantation followed by bortezomib and dexamethasone in Bence-Jones protein κ-type of multiple myeloma with systemic amyloidosis].
    Nagamachi Y; Yamauchi N; Muramatsu H; Miyajima N; Inomata H; Okamoto T; Nozawa E; Gotoh Y; Koyama R; Ihara K; Nishisato T; Kato J
    Rinsho Ketsueki; 2015 Mar; 56(3):323-8. PubMed ID: 25876787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
    Choufani EB; Sanchorawala V; Ernst T; Quillen K; Skinner M; Wright DG; Seldin DC
    Blood; 2001 Mar; 97(6):1885-7. PubMed ID: 11238135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis.
    Reynolds SB; Maghavani DP; Hashmi H
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31527206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
    Cordes S; Gertz MA; Buadi FK; Lin Y; Lacy MQ; Kapoor P; Kumar SK; McCurdy A; Dispenzieri A; Dingli D; Hayman SR; Hogan WJ; Pruthi RK
    Blood Coagul Fibrinolysis; 2016 Jan; 27(1):101-8. PubMed ID: 26218969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib: A Case Report and Review of the Literature.
    Jia J; Wang H; Wu M; Zhang F; Liu X; Chen W; Liu A
    Acta Haematol; 2018; 140(1):46-50. PubMed ID: 30114681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation.
    van Gameren II; Hazenberg BP; Jager PL; Smit JW; Vellenga E
    Amyloid; 2002 Sep; 9(3):165-74. PubMed ID: 12408679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Successful treatment with lenalidomide plus dexamethasone for multiple myeloma complicated with systemic amyloidosis].
    Fuchida S; Okano A; Hatsuse M; Murakami S; Haruyama H; Shimazaki C
    Rinsho Ketsueki; 2012 Nov; 53(11):1937-9. PubMed ID: 23257677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [AL amyloidosis-associated factor X deficiency].
    Croles FN; Beerenhout CH; Mulder AB; Meijer K; Nijziel MR
    Ned Tijdschr Geneeskd; 2014; 158(6):A6678. PubMed ID: 24495369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rapidly progressive AL amyloidosis in a patient with relapsed multiple myeloma after achieving a complete response to tandem autologous PBSCT].
    Yagi H; Ozaki S; Sekimoto E; Shibata H; Shigekiyo T; Satake N
    Rinsho Ketsueki; 2013 Dec; 54(12):2171-6. PubMed ID: 24452148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalization of plasma factor X levels in amyloidosis after plasma exchange.
    Beardell FV; Varma M; Martinez J
    Am J Hematol; 1997 Jan; 54(1):68-71. PubMed ID: 8980263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.